BIOMARIN PHARMACEUTICAL INC (BMRN) Fundamental Analysis & Valuation

NASDAQ:BMRN • US09061G1013

Current stock price

58.51 USD
-0.56 (-0.95%)
At close:
58.51 USD
0 (0%)
After Hours:

This BMRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. BMRN Profitability Analysis

1.1 Basic Checks

  • BMRN had positive earnings in the past year.
  • In the past year BMRN had a positive cash flow from operations.
  • Of the past 5 years BMRN 4 years were profitable.
  • BMRN had a positive operating cash flow in each of the past 5 years.
BMRN Yearly Net Income VS EBIT VS OCF VS FCFBMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M

1.2 Ratios

  • With an excellent Return On Assets value of 4.59%, BMRN belongs to the best of the industry, outperforming 90.93% of the companies in the same industry.
  • The Return On Equity of BMRN (5.73%) is better than 90.73% of its industry peers.
  • The Return On Invested Capital of BMRN (9.64%) is better than 94.02% of its industry peers.
  • BMRN had an Average Return On Invested Capital over the past 3 years of 6.29%. This is significantly below the industry average of 19.44%.
  • The 3 year average ROIC (6.29%) for BMRN is below the current ROIC(9.64%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.59%
ROE 5.73%
ROIC 9.64%
ROA(3y)4.38%
ROA(5y)2.86%
ROE(3y)5.55%
ROE(5y)3.65%
ROIC(3y)6.29%
ROIC(5y)N/A
BMRN Yearly ROA, ROE, ROICBMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 -20

1.3 Margins

  • Looking at the Profit Margin, with a value of 10.83%, BMRN belongs to the top of the industry, outperforming 90.93% of the companies in the same industry.
  • BMRN's Profit Margin has declined in the last couple of years.
  • BMRN has a better Operating Margin (27.06%) than 95.56% of its industry peers.
  • BMRN's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 81.43%, BMRN belongs to the top of the industry, outperforming 85.14% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BMRN has grown nicely.
Industry RankSector Rank
OM 27.06%
PM (TTM) 10.83%
GM 81.43%
OM growth 3Y106.3%
OM growth 5YN/A
PM growth 3Y17.04%
PM growth 5Y-25.17%
GM growth 3Y1.91%
GM growth 5Y2.54%
BMRN Yearly Profit, Operating, Gross MarginsBMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BMRN Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BMRN is creating some value.
  • Compared to 1 year ago, BMRN has more shares outstanding
  • BMRN has more shares outstanding than it did 5 years ago.
  • BMRN has a better debt/assets ratio than last year.
BMRN Yearly Shares OutstandingBMRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
BMRN Yearly Total Debt VS Total AssetsBMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 5.82 indicates that BMRN is not in any danger for bankruptcy at the moment.
  • BMRN's Altman-Z score of 5.82 is fine compared to the rest of the industry. BMRN outperforms 74.71% of its industry peers.
  • BMRN has a debt to FCF ratio of 0.83. This is a very positive value and a sign of high solvency as it would only need 0.83 years to pay back of all of its debts.
  • The Debt to FCF ratio of BMRN (0.83) is better than 94.98% of its industry peers.
  • A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.10, BMRN is not doing good in the industry: 61.97% of the companies in the same industry are doing better.
  • Although BMRN's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.83
Altman-Z 5.82
ROIC/WACC1.13
WACC8.55%
BMRN Yearly LT Debt VS Equity VS FCFBMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 5.21 indicates that BMRN has no problem at all paying its short term obligations.
  • BMRN has a Current ratio of 5.21. This is comparable to the rest of the industry: BMRN outperforms 58.11% of its industry peers.
  • BMRN has a Quick Ratio of 3.50. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.50, BMRN is in line with its industry, outperforming 43.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.21
Quick Ratio 3.5
BMRN Yearly Current Assets VS Current LiabilitesBMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BMRN Growth Analysis

3.1 Past

  • BMRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.46%.
  • BMRN shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -17.11% yearly.
  • Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 12.87% in the last year.
  • Measured over the past years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 11.60% on average per year.
EPS 1Y (TTM)-19.46%
EPS 3Y83.09%
EPS 5Y-17.11%
EPS Q2Q%-137.5%
Revenue 1Y (TTM)12.87%
Revenue growth 3Y15.4%
Revenue growth 5Y11.6%
Sales Q2Q%17.03%

3.2 Future

  • The Earnings Per Share is expected to grow by 41.22% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, BMRN will show a quite strong growth in Revenue. The Revenue will grow by 11.79% on average per year.
EPS Next Y162.78%
EPS Next 2Y77.74%
EPS Next 3Y58.77%
EPS Next 5Y41.22%
Revenue Next Year12.65%
Revenue Next 2Y12.03%
Revenue Next 3Y12.71%
Revenue Next 5Y11.79%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BMRN Yearly Revenue VS EstimatesBMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
BMRN Yearly EPS VS EstimatesBMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

8

4. BMRN Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 32.87, the valuation of BMRN can be described as expensive.
  • BMRN's Price/Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 92.08% of the companies in the same industry.
  • BMRN's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 25.70.
  • The Price/Forward Earnings ratio is 12.51, which indicates a correct valuation of BMRN.
  • 96.91% of the companies in the same industry are more expensive than BMRN, based on the Price/Forward Earnings ratio.
  • BMRN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.84.
Industry RankSector Rank
PE 32.87
Fwd PE 12.51
BMRN Price Earnings VS Forward Price EarningsBMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • BMRN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMRN is cheaper than 96.14% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BMRN is valued cheaply inside the industry as 96.53% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 15.69
EV/EBITDA 10.55
BMRN Per share dataBMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BMRN has an outstanding profitability rating, which may justify a higher PE ratio.
  • BMRN's earnings are expected to grow with 58.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.2
PEG (5Y)N/A
EPS Next 2Y77.74%
EPS Next 3Y58.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BMRN Dividend Analysis

5.1 Amount

  • No dividends for BMRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BMRN Fundamentals: All Metrics, Ratios and Statistics

BIOMARIN PHARMACEUTICAL INC

NASDAQ:BMRN (3/13/2026, 8:12:13 PM)

After market: 58.51 0 (0%)

58.51

-0.56 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-23
Earnings (Next)04-29
Inst Owners100.79%
Inst Owner Change4.8%
Ins Owners0.67%
Ins Owner Change-1.05%
Market Cap11.25B
Revenue(TTM)3.22B
Net Income(TTM)348.90M
Analysts81.25
Price Target92.49 (58.08%)
Short Float %4.5%
Short Ratio3.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-139.93%
Min EPS beat(2)-142.18%
Max EPS beat(2)-137.68%
EPS beat(4)2
Avg EPS beat(4)-50.99%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)-11.67%
EPS beat(12)8
Avg EPS beat(12)-5.02%
EPS beat(16)11
Avg EPS beat(16)-18.07%
Revenue beat(2)1
Avg Revenue beat(2)0.52%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)3.57%
Revenue beat(4)2
Avg Revenue beat(4)1.54%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)5
Avg Revenue beat(8)2.04%
Revenue beat(12)6
Avg Revenue beat(12)0.83%
Revenue beat(16)8
Avg Revenue beat(16)0.27%
PT rev (1m)-1.94%
PT rev (3m)-0.51%
EPS NQ rev (1m)-18.95%
EPS NQ rev (3m)-21.48%
EPS NY rev (1m)5.5%
EPS NY rev (3m)1.17%
Revenue NQ rev (1m)-6.66%
Revenue NQ rev (3m)-5.61%
Revenue NY rev (1m)2.73%
Revenue NY rev (3m)4.88%
Valuation
Industry RankSector Rank
PE 32.87
Fwd PE 12.51
P/S 3.49
P/FCF 15.69
P/OCF 13.59
P/B 1.85
P/tB 1.98
EV/EBITDA 10.55
EPS(TTM)1.78
EY3.04%
EPS(NY)4.68
Fwd EY7.99%
FCF(TTM)3.73
FCFY6.37%
OCF(TTM)4.31
OCFY7.36%
SpS16.75
BVpS31.65
TBVpS29.52
PEG (NY)0.2
PEG (5Y)N/A
Graham Number35.6
Profitability
Industry RankSector Rank
ROA 4.59%
ROE 5.73%
ROCE 12.75%
ROIC 9.64%
ROICexc 12.49%
ROICexgc 13.54%
OM 27.06%
PM (TTM) 10.83%
GM 81.43%
FCFM 22.26%
ROA(3y)4.38%
ROA(5y)2.86%
ROE(3y)5.55%
ROE(5y)3.65%
ROIC(3y)6.29%
ROIC(5y)N/A
ROICexc(3y)7.4%
ROICexc(5y)N/A
ROICexgc(3y)8.13%
ROICexgc(5y)N/A
ROCE(3y)8.32%
ROCE(5y)N/A
ROICexgc growth 3Y117.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y120.08%
ROICexc growth 5YN/A
OM growth 3Y106.3%
OM growth 5YN/A
PM growth 3Y17.04%
PM growth 5Y-25.17%
GM growth 3Y1.91%
GM growth 5Y2.54%
F-Score6
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.83
Debt/EBITDA 0.63
Cap/Depr 139.49%
Cap/Sales 3.45%
Interest Coverage 120.32
Cash Conversion 87.04%
Profit Quality 205.51%
Current Ratio 5.21
Quick Ratio 3.5
Altman-Z 5.82
F-Score6
WACC8.55%
ROIC/WACC1.13
Cap/Depr(3y)114.54%
Cap/Depr(5y)116.58%
Cap/Sales(3y)3.77%
Cap/Sales(5y)4.81%
Profit Quality(3y)115.9%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.46%
EPS 3Y83.09%
EPS 5Y-17.11%
EPS Q2Q%-137.5%
EPS Next Y162.78%
EPS Next 2Y77.74%
EPS Next 3Y58.77%
EPS Next 5Y41.22%
Revenue 1Y (TTM)12.87%
Revenue growth 3Y15.4%
Revenue growth 5Y11.6%
Sales Q2Q%17.03%
Revenue Next Year12.65%
Revenue Next 2Y12.03%
Revenue Next 3Y12.71%
Revenue Next 5Y11.79%
EBIT growth 1Y53.85%
EBIT growth 3Y138.08%
EBIT growth 5YN/A
EBIT Next Year63.85%
EBIT Next 3Y28.51%
EBIT Next 5Y24.75%
FCF growth 1Y50.82%
FCF growth 3Y152.76%
FCF growth 5YN/A
OCF growth 1Y44.54%
OCF growth 3Y67.59%
OCF growth 5Y57.51%

BIOMARIN PHARMACEUTICAL INC / BMRN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?

ChartMill assigns a fundamental rating of 7 / 10 to BMRN.


What is the valuation status for BMRN stock?

ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.


Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?

BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 8 / 10.


What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?

The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.


What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?

The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 162.78% in the next year.